All In Biotech

Drug Trial Radar · NCT05210790

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300; TAK-121) in Patients With Polycythemia Vera

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 293 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

293

Actual

Start

Apr 11, 2022

Primary completion

Feb 21, 2025

Study completion Aug 31, 2028

Sponsor

Lead sponsor
Protagonist Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Polycythemia vera (PV) is a long-term condition in which the bone marrow makes too many red blood cells (RBCs). Bone marrow is the soft tissue inside the large bones where blood cells are made. When there are too many RBCs, called erythrocytosis, the blood can become thicker and move less easily through blood vessels and organs. This can raise the risk of blood clots (thrombosis) in veins or arteries. Sometimes, these clots can be life-threatening and may cause a stroke or heart attack. Treatment aims to keep the percentage of RBCs in the blood (hematocrit) in a safe range. For adults with PV, this means keeping the hematocrit below 45%. This helps lower the blood thickness and the risk of thrombosis. PV can also be linked to low iron levels (iron deficiency), because the body uses iron to make more RBCs. Many people with PV are treated with blood removal (phlebotomy) to lower RBC levels in the blood. This can worsen the iron deficiency, because each blood removal also takes iron out of the body. Rusfertide is a medicine that lowers the amount of iron available in the blood. It works like hepcidin, a natural hormone that helps control iron levels in the body. By limiting iron available for RBC production, rusfertide may help keep hematocrit below 45% and may improve symptoms. It may also reduce, or even remove, the need for phlebotomy in people. The main aim of this study is to check how well rusfertide works compared with placebo to lower the number of phlebotomies. A placebo looks like rusfertide but does not have any medicine in it. Other aims are to learn how safe rusfertide is compared with placebo and to understand how well it works to reduce the need for phlebotomy and to keep hematocrit levels under control. The study also wants to learn how rusfertide moves through the body (pharmacokinetics) and how it affects the body (pharmacodynamics or PD). This study has 4 parts that follow each other: * In part 1a, participants will receive either rusfertide or placebo. * In part 1b, all participants will receive rusfertide. * In part 2, participants can continue to receive rusfertide if they benefit from treatment with rusfertide. * Part 3 will include participants who finish Part 2 and still benefit from rusfertide. During the study, participants will visit the study clinical several times at fixed timepoints.

Conditions

  • Polycythemia Vera

Interventions

  • RusfertideDrug

    Rusfertide SC injection

  • PlaceboDrug

    Rusfertide-matching placebo SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1a: Percentage of Participants Who Achieved ResponseTime frame: From Weeks 20 to 32

Locations

184 sites in 20 countries. Site status is shown where the registry gives one.

  • Infirmary Cancer Care

    Mobile, Alabama

  • Palo Verde Hematology-Oncology

    Glendale, Arizona

  • City of Hope Medical Center, Duarte

    Duarte, California

  • California Cancer Associates for Research and Excellence - Fresno

    Fresno, California

  • Marin Cancer Care

    Greenbrae, California

  • City of Hope Medical Center, Lenner

    Irvine, California

  • University of California, San Diego (UCSD) - Moores Cancer Center

    La Jolla, California

  • University of California, Los Angeles (UCLA) - Medical Center

    Los Angeles, California

  • Stanford University

    Palo Alto, California

  • Pomona Valley Hospital Medical Center

    Pomona, California

  • Sharp Memorial Hospital

    San Diego, California

  • University of California, San Francisco

    San Francisco, California

  • City of Hope Medical Center, Upland

    Upland, California

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • University of Colorado - Aurora Cancer Center

    Aurora, Colorado

  • Rocky Mountain Cancer Centers - Boulder

    Boulder, Colorado

  • Rocky Mountain Cancer Centers

    Colorado Springs, Colorado

  • Rocky Mountain Cancer Centers

    Colorado Springs, Colorado

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Rocky Mountain Cancer Centers

    Lakewood, Colorado

  • Rocky Mountain Cancer Centers

    Littleton, Colorado

  • Rocky Mountain Cancer Centers

    Lone Tree, Colorado

  • Yale University School of Medicine - Yale Cancer Center

    New Haven, Connecticut

  • BRCR Medical Center

    Plantation, Florida

  • BayCare Suncoast Medical Clinic - Hematology/Oncology

    St. Petersburg, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois

  • Northwest Oncology and Hematology

    Rolling Meadows, Illinois

  • Orchard Healthcare Research Inc

    Skokie, Illinois

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana

  • Mission Cancer & Blood

    Des Moines, Iowa

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • Pontchartrain Cancer Center

    Covington, Louisiana

  • Pontchartrain Cancer Center

    Hammond, Louisiana

  • American Oncology Partners of Maryland PA (Center for Cancer & Blood Disorders)

    Bethesda, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • Cancer Care Specialists

    Reno, Nevada

  • Memorial Sloan Kettering Cancer Center - BASKING RIDGE

    Basking Ridge, New Jersey

Showing 40 of 184 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.